NCT05827081 2026-03-02
Adjuvant WIDER
Novartis
Phase 3 Recruiting
Clinical Trials
46 trialsNCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT02960022 2025-12-17
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02319837 2025-07-08
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT05440383 2025-03-14
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03035032 2024-11-26
A Study of ELIGARDĀ® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
NCT06490328 2024-07-08
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Dongkook Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT01326312 2023-06-22
GTx758
GTx
Phase 2 Terminated
NCT02663908 2022-06-29
PRONOUNCE
Ferring Pharmaceuticals
Phase 3 Terminated
NCT05304169 2022-03-31
PRIZE
Zodiac Produtos Farmaceuticos S.A.
Phase 4 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT04783636 2021-03-17
To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
Peptron, Inc.
Phase 1 Unknown
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT03662958 2018-09-10
Comparison of a Novel Leuprolide With Market Leuprolide
Lee's Pharmaceutical Limited
Phase NA Unknown
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT02107391 2017-05-24
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT02212197 2017-04-25
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Camurus AB
Phase 2 Completed
NCT01933022 2017-03-09
EFFECT
Astellas Pharma Inc
Phase 4 Terminated
NCT01415960 2017-03-03
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
GP-Pharm
Phase 3 Completed
NCT03029533 2017-01-24
Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer
Daewoong Pharmaceutical Co. LTD.
Phase 1 Unknown
NCT00928434 2016-12-13
A Study of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT01011751 2015-07-30
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Phase 3 Completed
NCT00817739 2015-07-29
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
Takeda
Phase 2 Completed
NCT00683917 2014-08-21
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT01069094 2014-06-30
A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
Repros Therapeutics Inc.
Phase 1/2 Completed
NCT00378690 2014-06-04
ICELAND
Astellas Pharma Inc
Phase 3 Completed
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT00514917 2013-11-04
Rising PSA
Sanofi
Phase 3 Terminated
NCT01161563 2013-09-06
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
Phase 4 Completed
NCT00924469 2013-04-17
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT00451958 2013-03-21
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Ferring Pharmaceuticals
Phase 3 Completed
NCT00295750 2012-12-19
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00075192 2012-06-06
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
AstraZeneca
Phase 1/2 Completed
NCT01132404 2012-01-31
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Millennium Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT00805935 2012-01-27
MenopurĀ® Versus FollistimĀ® in Polycystic Ovarian Syndrome (PCOS)
Ferring Pharmaceuticals
Phase 4 Completed
NCT00283062 2012-01-26
Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
Sanofi
Phase 3 Completed
NCT00626431 2011-07-19
A Study of Leuprolide to Treat Prostate Cancer
Abbott
Phase 3 Completed
NCT00598312 2010-09-08
Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed
NCT00776074 2010-06-22
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.
Takeda
Phase 2 Completed
NCT00056654 2008-09-17
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
Abbott
Phase NA Completed
NCT00076531 2008-01-28
Clinical Trial for Prostate Cancer
Oakwood Laboratories, LLC
Phase 3 Completed